Are patients after transcatheter aortic valve replacement (TAVR) typically paced transvenously?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 2, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Transvenous Pacing After TAVR: Risk-Stratified Approach

Not all TAVR patients require transvenous pacing post-operatively—the decision is based on specific high-risk conduction features identified during or immediately after the procedure. 1

Who Requires Transvenous Pacing Post-TAVR

Mandatory Transvenous Pacing (≥24 hours)

Patients with pre-existing RBBB should maintain transvenous pacing ability with continuous cardiac monitoring for at least 24 hours, regardless of new ECG changes. The risk of high-degree AV block in this population reaches 24% and persists up to 7 days post-procedure, with associated mortality risk. 1

Patients who develop new LBBB or PR/QRS prolongation ≥20 ms (without pre-existing RBBB) warrant continued transvenous pacing for at least 24 hours alongside continuous monitoring and daily ECGs. 1

Any transient high-grade AV block during valve deployment mandates maintaining the transvenous pacemaker for at least 24 hours, irrespective of baseline conduction status. 1

Transient or persistent high-grade AV block during/after TAVR requires leaving the temporary pacemaker in place for at least 24 hours to assess conduction recovery. 1

Patients Who Do NOT Require Transvenous Pacing

Patients can be considered for early discharge without transvenous pacing if they meet ALL of the following criteria:

  • No primary PPM indication
  • No new first-degree AV block
  • No new bundle branch block
  • No progression of baseline conduction disturbance (QRS prolongation <20 ms)
  • Narrow QRS before and after TAVR 1

Critical Management Considerations

Recovery Location Requirements

When transvenous pacemakers are removed in high-risk patients (pre-existing RBBB or new conduction abnormalities), the recovery location must accommodate emergent pacing capability. This means step-down or ICU settings with maintained indwelling vascular access for rapid pacemaker reinsertion if needed. 1

Delayed High-Grade AV Block Risk

Approximately 10% of patients develop delayed high-grade AV block (>2 days post-procedure or after discharge). Pre-existing RBBB and new LBBB are risk factors, though insufficient for preemptive permanent pacing decisions. 1

Predictive Testing Strategy

Atrial pacing immediately post-TAVR can predict permanent pacemaker need: patients who do NOT develop Wenckebach AV block with right atrial pacing (up to 120 bpm) have only 1.3% risk of requiring permanent pacing by 30 days, versus 13.1% in those who do develop Wenckebach. 1

Permanent Pacemaker Decision Points

Persistent high-grade AV block requires permanent pacemaker implantation. 1

Recurrent episodes of transient high-grade AV block (intraoperative or postoperative) should prompt permanent pacemaker consideration before discharge, regardless of symptoms. 1

In patients with prior RBBB who develop transient or persistent procedural high-grade AV block, permanent pacing is indicated in the vast majority of cases, with high anticipated ventricular pacing requirements. A durable transvenous pacing lead should be placed before leaving the procedure suite. 1

Common Pitfalls

The most significant pitfall is premature removal of transvenous pacing in high-risk patients (particularly those with pre-existing RBBB) without ensuring appropriate monitoring capabilities and vascular access for emergent re-pacing. The latent risk of high-degree AV block extends up to 7 days, especially with self-expanding valves. 1

Another critical error is routine permanent pacemaker implantation for new LBBB alone—while new LBBB increases permanent pacemaker risk (19.7% vs 7.1% without LBBB), early permanent pacing does not protect against increased mortality associated with new LBBB. 2

References

Related Questions

In a patient five days after transcatheter aortic valve implantation who has an almost isorhythmic atrioventricular dissociation caused by an altered junctional automatic focus competing with the sinus node, with normal sinus conduction to the ventricles, unchanged QRS morphology and AV interval, and no evidence of advanced AV‑node disease, should a permanent pacemaker be implanted?
How should a widened QRS complex on an ECG be managed?
In a 12-year-old child with dry cough, expiratory wheezing, and nasal congestion but no prior history of asthma, what is the appropriate evaluation and management?
What chemical deep vein thrombosis prophylaxis regimen (drug, dose, timing, and duration) should be used after colon cancer resection in an adult patient with normal renal function?
Should I start a patient on Qlbree (viloxazine) rather than Strattera (atomoxetine) for ADHD, since Strattera is flagged yellow on Gensight and Qlbree is green?
What progesterone regimen is recommended for the treatment of menorrhagia?
What is the recommended pharmacologic venous thromboembolism prophylaxis for a chronic dialysis patient after colon cancer resection?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.